tbuckley/cabot-search huggingface dataset:
Isotopic Method for Determination of Vitamin B12 Levels in Blood
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CHLOROFORM AS AN ANÆSTHETIC.
Journal: JAMA (1892)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Bevacizumab in combination with 5-FU/leucovorin improves survival in patients with metastatic colorectal cancer: A combined analysis
Authors: R. D. Mass, G. Fyfe, J. Hambleton, F. Kabbinavar, H. Hurwitz, W. Novotny, S. Sarkar
Journal: Journal of Clinical Oncology (2004)

3616 Background: Bevacizumab [Avastin (BV)], a recombinant, humanized monoclonal antibody against VEGF, improves survival in combination with chemotherapy for first line treatment of metastatic colorectal cancer (CRC). In a randomized, placebo-controlled phase III study, the addition of BV to irinotecan/5-FU/Leucovorin (IFL) resulted in significant improvement in survival compared with IFL alone (p=0.00004; median survival increased from 15.6 months to 20.3 months). BV has been combined with 5-FU/leucovorin (LV) alone in 3 randomized studies (see table). In the phase III study, a third treatment arm of BV/5-FU/LV was included until the safety of IFL/BV was demonstrated in a pre-specified analysis. BV/5-FU/LV has been studied in 2 randomized phase II studies. In the larger phase II study, patient characteristics were similar to those in the phase III study with the exception that median age was 71 compared with 60 years, and ECOG performance status â‰¥ 1 was 72% versus 41% of patients. Combining the patient data from these 3 studies allows a more robust evaluation of efficacy and safety of BV/5-FU/LV in comparison with a combined control of 5-FU/LV and IFL. Methods: The combined control group included patients with metastatic CRC randomized to 5-FU/LV or to IFL. The comparator arm included patients randomized in these same studies to BV/5-FU/LV. BV dosing was 5mg/kg every 2 weeks in all patients evaluated. Results: The efficacy results are shown below. There was a 26% reduction in daily risk of death with BV/5-FU/LV compared with 5-FU/LV or IFL alone (hazard ratio 0.742; 95% CI: 0.59, 0.93). Adverse events were consistent with those previously reported. Conclusion: This large combined analysis confirms that the combination of Bevacizumab with 5 FU/LV improves survival and progression-free survival compared with 5-FU/LV or IFL alone. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Genentech Genentech Genentech
Endoscopic Ultrasonography
Authors: A Chak
Journal: Endoscopy (2000)

Endosonography is primarily a diagnostic imaging modality, but new therapeutic applications are being developed. Miniprobe technology (ultrasound catheter probes) has led to new clinical applications. The staging of gastrointestinal cancers remains the major accepted indication for endosonography. Other conditions, such as chronic pancreatitis, portal hypertension, and inflammatory bowel diseases, are also being evaluated with endosonographic imaging.
Should Married Women Work?
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Beauty Parlor Stroke: When a Beautician Becomes a Physician-Reply
Authors: Michael I. Weintraub
Journal: JAMA (1993)

<h3>In Reply.</h3> —I wish to thank Drs Beringer and Golden for this opportunity to expand on my article. Beringer wants more information. Patients 1 and 5 developed acute neurological dysfunction during the shampoo procedure, bringing it to a halt. In each case, the patient was immediately hospitalized. Patients 2,3, and 4 noted symptoms of brainstem dysfunction at the conclusion of the shampooing procedure when they stood up. They subsequently sought medical attention. The biomechanics of the shampooing procedure require the head to be placed in a recessed sink with the assumption of the hanging neck and head position. Reliable data about the extent and duration of forces applied by different beauticians, as well as the specific angulation achieved and the ischemic threshold of the individual, are not known nor have they ever been standardized. Despite these theoretical drawbacks and lack of quantification, the occurrence of stroke during this procedure suggests
Unanswered questions about DNR orders
Authors: B. Lo
Journal: JAMA (1991)

Everyone who dies suffers a cardiac arrest. Cardiopulmonary resuscitation (CPR) can revive patients after they experience unexpected cardiac arrests and restore them to vigorous health. But for persons with progressive chronic illness, CPR is more likely to prolong death than prevent it. The thoughtful guidelines promulgated by the American Medical Association (AMA) concerning do-not-resuscitate (DNR) orders<sup>1</sup>deserve careful reading by all physicians, but they do not address several important questions. Furthermore, on some issues, reasonable physicians will disagree, perhaps intensely. <h3>When Is CPR Futile?</h3> It is irrational to provide CPR when it would be futile. But while this general rule seems obvious, it may be difficult to decide, in particular cases, whether CPR would be "futile." The term<i>futile</i>is used in many different ways.<sup>2</sup>In a strict sense, treatment is futile when it offers no benefit to the patient, because maximal therapy has failed and physiologic improvement is
Science and Politics
Journal: JAMA (2006)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Annual Reprint of the Reports of the Council on Pharmacy and Chemistry of the American Medical Association for 1932. With the Comments That Have Appeared in The Journal.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reduced NFAT1 Protein Expression in Human Umbilical Cord Blood T Lymphocytes
Authors: Suzanne Kadereit, Shaden F. Mohammad, Robin E. Miller, Kathleen Daum Woods, Chad D. Listrom, Karen McKinnon, Alborz Alali, Linda S. Bos, Michelle L. Iacobucci, Michael R. Sramkoski, James W. Jacobberger, Mary J. Laughlin
Journal: Blood (1999)
The Dartmouth Medical School
Journal: New England Journal of Medicine (1959)

The study explored the feasibility and efficacy of a manualized cognitive restructuring program for treating adolescents suffering from posttraumatic stress disorder (PTSD).Nine girls and 3 boys (mean age 16 years; range ϭ 14 -18), with PTSD, were recruited from a community mental health center and a tertiary health care center and enrolled in a pilot study.The adolescents were seen weekly for 12-16 weeks of individual treatment.Variables assessed included: trauma history, PTSD diagnosis and severity, depression, substance abuse, and client satisfaction.Twelve adolescents consented to treatment; 9 completed the program.The number of types of traumas reported averaged 6.5 (range ϭ 1-13).Paired t tests were used to test prepost change for PTSD symptoms and depression, in completers.From baseline to posttreatment, there were statistically significant improvements in PTSD and depression.Treatment gains were maintained at 3 month follow-up.Preliminary results suggest the feasibility of implementing a manualized cognitive restructuring program to treat PTSD in adolescents.Completers rated themselves as improved and satisfied at posttreatment and 3-month follow-up.Feedback from referring clinicians also indicated high satisfaction.
Lupoid Hepatitis: Report of a Case Followed by Serial Liver Biopsies
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ZW25 Effective in HER2-Positive Cancers
Journal: Cancer Discovery (2018)

A novel anti-HER2 therapy, ZW25, may be effective and well tolerated in patients with a variety of HER2-positive cancers. In a phase I trial, patients treated with the drug-most of whom had gastroesophageal or colorectal cancer-had an objective response rate of 41% and mild side effects.
Carcinoma of the esophagus. Long-term results
Authors: E. F. Parker
Journal: JAMA (1976)

Between 1940 and 1967, we treated 609 patients with primary carcinoma of the esophagus by three different methods. In the first group of 170 patients, surgical resection predominated. In the next 166 patients, radiation therapy was used as the primary method. In a third group (135 patients) and a fourth group (138 patients), radiation therapy was followed by resection in the operable cases. After comparing the results of the three methods, we believe that radiation therapy followed by resection produces the best results. Moreover, this approach Is Justified by the discovery of residual carcinoma In most surgical specimens from patients who have had radiation therapy. (<i>JAMA</i>235:1018-1020, 1976)
Continuing Medical Education
Journal: JAMA (1973)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Toxicology of Haloacetonitriles
Authors: Johnnie R. Hayes, Lyman W. Condie, Joseph F. Borzelleca
Journal: Environmental Health Perspectives (1986)

Haloacetonitriles are by-products of water chlorination and may form in vivo from the reaction of residual chlorine with endogenous compounds such as amino acids. Dibromoacetonitrile (DBAN) was negative in selected mutagenic assays; dichloroacetonitrile (DCAN) was mutagenic in S. typhimurium, but not in S. cerevisiae. Both DBAN and DCAN may be carcinogenic. There is a paucity of basic toxicological data for these compounds. The studies described were conducted to determine the acute, subacute, and subchronic toxicity of DBAN and DCAN. The acute oral LD50 values (mg/kg) in mice and rats are: DBAN, mice: 289 (M), 303 (F); DBAN, rats: 245 (M), 361 (F); DCAN, mice: 270 (M), 279 (F); DCAN, rats: 339 (M), 330 (F). Death was preceded by slowed respiration, depressed activity, prostration, and coma. There were no apparent compound-related gross pathological effects. DBAN (in corn oil) was administered by gavage to male and female CD rats for 14 or 90 days at levels of 23, 45, 90, and 180 mg/kg/day or 6, 23, and 45 mg/kg/day, respectively. Mortality was 100% at 180 mg/kg and 40% (M) and 20% (F) at 90 mg/kg/day. Compound-related mortality was 10% (M) and 5% (F) at 45 mg/kg and 0% (M) and 10% (F) at 23 mg/kg during the 90-day study. No consistent, significant, adverse compound-related effects on any of the parameters evaluated were evident. Possible target organs might be spleen, thymus, and liver. The no-observed adverse-effect level (NOAEL) for 14 days was 45 mg/kg/day and for 90 days was 23 mg/kg/day. DCAN (in corn oil) was administered by gavage to male and female CD rats for 14 or 90 days at levels of 12, 23, 45, and 90 mg/kg/day or 8, 33, and 65 mg/kg/day, respectively. There were no deaths during the 14-day study. Compound-related mortality was 50% (M) and 25% (F) at 65 mg/kg, 10% (M) and 5% (F) at 33 mg/kg, and 5% (M) and 0% (F) at 8 mg/kg during the 90-day study. Body weights were significantly lower at 90 and 65 mg/kg/day; weight and ratios of spleen and gonads and cholesterol levels were significantly lower at 90 mg/kg/day. No consistent, significant adverse compound-related effects on any of the parameters evaluated were evident. The NOAEL for 14 days was 45 mg/kg/day and for 90 days was 8 mg/kg/day.
Family Practice
Authors: Nicholas J. Pisacano
Journal: JAMA (1979)

"Distat opus nostrum; sed fontibus exit ab isdem."† Ovid It is especially appropriate this year to update and review major events in the specialty of family practice, for it was almost ten years ago to the day (February 1969) that family practice, albeit only after a long and operose struggle, officially became the 20th medical specialty. Like the phoenix, which is represented on the American Board of Family Practice (ABFP) seal, the specialty rose from the ashes of what was called general practice—the residue of physicians who remained after all the others had entered a more circumscribed field of medicine. Family practice was born out of social need to fill the void created by this specialization in other more specific areas of medicine. The call was for a "broader" specialty, one that would train the "new physician" in the "old-fashioned" relationships, a physician who would not only appreciate the patient
Booknote
Journal: JAMA (1990)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Maternal primary hyperparathyroidism of pregnancy. Successful treatment by parathyroidectomy
Authors: R. F. Gaeke
Journal: JAMA (1977)

Primary hyperparathyroidism of pregnancy may result in spontaneous abortion, neonatal hypocalcemia, or neonatal tetany if appropriate treatment is not instituted. Of great importance in prevention of these complications is an awareness by physicians that this disease exists and is of clinical importance. Parathyroidectomy performed during the second trimester of pregnancy offers the best chance for fetal and neonatal survival. This operation results in little risk to either the mother or the fetus. Normal calcium homeostasis is restored to the fetus and the risk of hypocalcemia in the neonatal period is virtually eliminated. (<i>JAMA</i>238:508-509, 1977)
Eurosurveillance achievements in 2008 and challenges for 2009
Authors: None Eurosurveillance editorial team
Journal: Eurosurveillance (2009)

2008 was yet another year of major innovations for Eurosurveillance. Since January 2008, Eurosurveillance has been published once a week online with short, rapid communications as well as longer papers on the surveillance, prevention and control of communicable diseases.